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Abstract
Background This pilot study assessed the diagnostic
accuracy of rapid evaporative ionization mass spectrometry
(REIMS) in colorectal cancer (CRC) and colonic
adenomas.
Methods Patients undergoing elective surgical resection
for CRC were recruited at St. Mary’s Hospital London and
The Royal Marsden Hospital, UK. Ex vivo analysis was
performed using a standard electrosurgery handpiece with
aspiration of the electrosurgical aerosol to a Xevo G2-S
iKnife QTof mass spectrometer (Waters Corporation).
Histological examination was performed for validation
purposes. Multivariate analysis was performed using prin-
cipal component analysis and linear discriminant analysis
in Matlab 2015a (Mathworks, Natick, MA). A modified
REIMS endoscopic snare was developed (Medwork) and
used prospectively in five patients to assess its feasibility
during hot snare polypectomy.
Results Twenty-eight patients were recruited (12 males,
median age 71, range 35–89). REIMS was able to reliably
distinguish between cancer and normal adjacent mucosa
(NAM) (AUC 0.96) and between NAM and adenoma
(AUC 0.99). It had an overall accuracy of 94.4 % for the
detection of cancer versus adenoma and an adenoma sen-
sitivity of 78.6 % and specificity of 97.3 % (AUC 0.99)
versus cancer. Long-chain phosphatidylserines (e.g., PS
22:0) and bacterial phosphatidylglycerols were over-ex-
pressed on cancer samples, while NAM was defined by
raised plasmalogens and triacylglycerols expression and
adenomas demonstrated an over-expression of ceramides.
REIMS was able to classify samples according to tumor
differentiation, tumor budding, lymphovascular invasion,
extramural vascular invasion and lymph node
micrometastases (AUC’s 0.88, 0.87, 0.83, 0.81 and 0.81,
respectively). During endoscopic deployment, colono-
scopic REIMS was able to detect target lipid species such
as ceramides during hot snare polypectomy.
Conclusion REIMS demonstrates high diagnostic accuracy
for tumor type and for established histological features of
poor prognostic outcome in CRC based on a multivariate
analysis of the mucosal lipidome. REIMS could augment
endoscopic and imaging technologies for precision phe-
notyping of colorectal cancer.
Keywords Rapid evaporative ionization mass
spectrometry  Colorectal cancer  Metabolic
Precision medicine aims to improve patient outcomes, by
coupling established clinical–pathological indexes with
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and Other Interventional Techniques 
state-of-the-art molecular profiling to create diagnostic,
prognostic and therapeutic strategies precisely tailored to
each patient’s requirements [1, 2]. There is an unmet need
for precision polyp and cancer phenotyping for stratifica-
tion of surgical and neoadjuvant therapies in the treatment
of colorectal cancer. In the management of complex rectal
polyps and early rectal cancer, the decision to proceed to a
radical resection is largely based on a combination of
imaging and clinical assessment. Current protocols for risk
stratification of polyps are based on subjective descriptions
of polyp morphology such as the Paris classification
although these are not highly reproducible [3] and
histopathological analysis is also subjective.
Rapid evaporative ionization mass spectrometry
(REIMS) is a novel technique based on the mass spectro-
metric analysis of the aerosol produced during electrosur-
gical diathermy to provide tissue specific diagnostics based
on lipid profiles [4–6]. This technology is able to provide
rapid metabolic phenotyping of rectal and colonic cancers
using the mass spectrometric lipid signatures for the
identification of unknown tissue features intra-operatively
with correct classification efficiencies exceeding 92 % in
real-time and 97 % for ex vivo analyses [7]. Recently, we
have demonstrated that this technology can be deployed
endoluminally in the upper and lower GI tract; however, its
true application in colonoscopy is not yet known [8]. As a
follow-up to our earlier work, in this pilot study, we
assessed the accuracy of endoscopic REIMS for the clas-
sification of both benign and neoplastic colorectal lesions
and to provide chemical information associated with poor
prognostic histological features commonly assessed in
colorectal cancer. The aim was to assess the feasibility of
this technology to provide information of clinical utility,
and this was achieved using an ex vivo analysis of tissue
samples, which permits the creation of a spectral database
for prospective use. The secondary aim was to further
demonstrate that in vivo applications of endoscopic
REIMS could be scaled and reliably reproduced. A proto-
type was therefore developed for deployment of REIMS
during colonoscopy.
Methods
Patient recruitment and sampling
Between January and March 2015, 28 patients undergoing
elective surgical treatment for colorectal cancer were
prospectively recruited at two London teaching hospitals
(St Mary’s Hospital and The Royal Marsden Hospital). Full
local ethical approval was obtained (14/EE/0024). Inclu-
sion criteria were adult patients with a suspected primary
colorectal cancer undergoing elective surgical resection by
either open or laparoscopic surgery. Patients who had
undergone neoadjuvant chemoradiotherapy were included.
Patients unable to provide consent or those undergoing
emergency surgery were excluded, as were patients with
tumors associated with hereditary conditions such as
Familial Adenomatous Polyposis, Hereditary Nonpolyposis
Colorectal Cancer or inflammatory bowel disease. The
primary endpoint of the study was the diagnosis of col-
orectal cancer, as differentiated from adenoma and nor-
mal adjacent mucosa (NAM). Secondary endpoints were
the diagnosis of histological prognostic biomarkers: TNM
stage, tumor differentiation, lymphovascular invasion,
extramural vascular invasion and tumor budding and
complete pathological response (cPR) to neoadjuvant
therapy. Following resection, surgical specimens were
immediately transported fresh to the histopathology
department by a member of the research team. The speci-
men was opened by a trained histopathologist, and fresh
biopsies were cut from the tumor and normal adjacent
mucosa at 10 cm from the lesion.
Ex vivo analysis
The fresh biopsies were analyzed ex vivo with an elec-
trosurgery hand-piece using monopolar diathermy in cut-
ting mode (ValleylabTM) with aspiration of the
electrosurgical aerosol to a Xevo G2-S iKnife Q-Tof mass
spectrometer (Waters Corporation). Following formalin
fixation, the biopsies underwent histological examination
by two trained histopathologists (AS & RG) for validation
purposes. Full classification was performed according to
the minimum dataset recommendations of the Royal Col-
lege of Pathologists [9].
Statistical analysis
Four high-quality mass spectra were obtained per sample.
REIMS raw spectral data were converted to imzML format
(MSConvert) and imported into Matlab R2015a (Math-
works, Natick, MA) for processing within a toolbox
designed in-house for interrogation of clinical mass spec-
tral datasets. The compiled spectra were normalized to
their total ion count to reduce the impact of variation in
overall signal intensity unrelated to spectral pattern and
then log transformed to account for large variability dif-
ferences between small and large peaks across mass spectra
[10]. Discriminating models were then subjected to
dimensionality reduction via principal components analysis
to reduce the number of observed variables into a smaller
number of orthogonal principal components, which
account for the majority of the variance in the dataset. The
first 30 principal components were kept for further analy-
sis. Linear discriminant analysis was then used to
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maximize the separation between different classes, and the
resulting LDA space was used for classification of spectra
from unknown tissue samples using Mahalanobis distance
calculations. All mass spectral data belonging to one
patient were left out of the sample set, and a new model
was calculated using the remaining data. The withheld data
were projected into the new model and classified as one
tissue type using Mahalanobis distances calculations, per-
formed between the unknown sample point and calculated
class centers. This process was repeated for each individual
patient. From this, the diagnostic sensitivity and specificity
could be calculated as were ROC curves to provide a cross-
validated score that describes the clinical utility of the
model. To identify statistically significant peaks responsi-
ble for prediction into each class, for each cross-validation
iteration, analysis of variance (ANOVA) was employed to
only select the features most statistically significant
(p value\ 0.05) for PCA-LDA classification into each
group. Exact m/z values were retrieved from the raw data,
and these values were used for compound identification via
database search (Metlin).
Results
Twenty-eight patients were recruited for the ex vivo phase
of the study (12 males, 16 females). Two patients were
subsequently excluded from the final analysis: In one case,
it was not possible to acquire a tissue sample for REIMS
analysis because the tumor was not sufficient (a minimum
tumor size of 10 mm diameter was required by the
histopathologist for research sampling); in the other case, it
was not possible to obtain adequate spectra from the
REIMS instrument, and the signal-to-noise ratio was too
low. Patient demographics and histological classification of
the remaining cases are shown in Table 1. Two patients
had an adenoma, fifteen patients had adenocarcinoma,
eight patients had mucinous adenocarcinoma, and one
patient had a gastrointestinal stromal tumor (GIST).
Diagnostic accuracy and histological biomarker
association
Representative REIMS spectra from NAM, a cancer and an
adenoma can be seen in Fig. 1. REIMS was able to reliably
distinguish between NAM and cancer (AUC 0.96) and
between NAM and adenoma (AUC 0.99). It had an overall
accuracy of 94.4 % for the detection of cancer versus
adenoma (Table 2) and an adenoma sensitivity of 78.6 %
and specificity of 97.3 % (AUC 0.99) versus cancer
(Fig. 2). Univariate analysis of target metabolites was
performed based on results from the loadings data to
confirm their statistical contribution to the model and to
identify descriptive metabolites responsible for class
description (Table 3). This confirms that lipid expression in
cancer is dynamic, and quantitative changes in target lipids
can be identified between pathological disease states.
Cancer has an over-expression of long-chain phos-
phatidylserines (e.g., PS 22:0) and bacterial
Table 1 Patient demographics and histopathological classification
from ex vivo analysis
Male/female 11/15
Median age (range) 71 (35–89)
Primary/recurrence 24/2
Neoadjuvant treatment 4
Site of lesion
Cecum 6
Ascending colon 1
Transverse colon 2
Descending colon 0
Sigmoid colon 7
Rectum 10
Histopathology
Adenoma 2a
Adenocarcinoma 15
Mucinous adenocarcinoma 8
Gastrointestinal stromal tumor (GIST) 1
Tumor differentiation
Well 1
Moderate 16
Poor 5
Not applicable 4b
T stage
T0 4b
T1 1
T2 5
T3 11
T4 5
N stage
N0 19
N1 6
N2 1
M stage
M0 25
M1 1
Extramural vascular invasion 7
Lymphovascular invasion 9
Tumor budding 16
a Benign histology but with suspicious features on preoperative
imaging
b In addition to the two patients’ tumors which were histologically
adenomas, two patients had no viable tumor remaining after complete
pathological response to neoadjuvant therapy
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Table 2 Summary diagnostic and sensitivity data from the multivariate models
Spectra
n =
Accuracy True
positive
True
negative
False
positive
False
negative
AUC
Diagnostic markers all
Cancer versus NAM 220 90.5 % 86.7 % 92.4 % 13.3 % 7.6 % 0.96
Cancer versus adenoma 89 94.4 % 78.6 % 97.3 % 2.7 % 21.4 % 0.99
Adenoma versus NAM 159 97.5 % 85.7 % 98.6 % 1.4 % 14.3 % 0.99
Histological subtype (mucinous vs.
adenocarcinoma)
75 90 % 94.2 % 83.3 % 16.7 % 5.8 % 0.96
Prognostic performance—whole model
Tumor differentiation (mod vs. poor) 183 83.1 % 68.3 % 87.3 % 12.7 % 31.7 % 0.88
Tumor budding 234 78.2 % 80.6 % 74.4 % 25.6 % 19.4 % 0.87
LVI 234 73.9 % 71.6 % 75.3 % 24.7 % 28.4 % 0.83
EMVI 234 73.5 % 65.3 % 77.2 % 22.8 % 34.7 % 0.81
?ve nodes 234 77.4 % 69.0 % 81.0 % 19.0 % 31.0 % 0.81
Rectal cancer prognostic factors
Differentiation (mod vs. poor) 84 94.4 % 78.6 % 98.2 % 1.8 % 21.4 % 0.99
Tumor budding 84 84.5 % 88.1 % 70.6 % 29.4 % 11.9 % 0.82
LVI 84 71.4 % 72.4 % 30.8 % 69.2 % 27.6 % 0.75
EMVI 84 96.4 % 85.7 % 98.6 % 14.3 % 1.4 % 0.98
?ve nodes 84 92.9 % 83.3 % 94.4 % 5.6 % 16.7 % 0.92
LCRT versus none 75 96 % 95.7 % 96.2 % 3.8 % 4.3 % 0.99
cPR versus NAM 52 100 % 100 % 100 % 0 % 0 % 1
AUC area under curve, NAM normal adjacent mucosa, Mod moderate, LCRT long-course chemoradiotherapy, cPR complete pathological
response
Table 3 Summary putative
metabolite IDs for cancer,
adenoma and normal colonic
mucosa, their m/z and statistical
significance (p value)
m/z Putative molecular structure p value Cancer Adenoma Normal
633.465 PA (31:0) 0.0001
642.495 GlcCer (30:1) 2.47E−12
653.495 1,2-DG (36:3) 0.0002
673.485 PA (34:0) 3.33E−16
699.505 PA 1.12E−07
702.625 Cer (D18:0/H24:0) 2.28E−11
710.485 PE (34:4) 6.73E−08
718.615 Cer(T18:0/24:0(2OH)) 9.30E−10
775.545 PG (36:1) 0.0001
797.535 PG (38:4) 0.004
864.675 Plasmalogen 0.0004
880.665 PS (43:4) 1.86E−07
886.565 PS (44:6) 1.110E−16
886.565 PS (44:8) 1.110E−16
888.75 PS (41:0) 1.38E−12
891.725 TG (54:0) 1.63E−08
The array visualization demonstrates if the metabolites were over-expressed (red) or under-expressed
(green) in specific histological states of cancer, adenoma or normal associated mucosa
Surg Endosc
123
phosphatidylglycerols, while healthy mucosa has an over-
expression of plasmalogens and triacylglycerols (Fig. 1;
Table 3), and adenomas demonstrated an over-expression
of ceramides (Fig. 1).
To assess the influence of possible patient confounders
on the model’s performance, the spectral data were mod-
eled against age and sex, and it was not possible to build a
strongly predictive model for either of these factors (Supp.
Figure 1 a and b). However, males and patients over the
age of 70 did demonstrate discrete clustering, suggesting
that there may be both age and sex subtle changes
detectable in the colonic mucosa. Analysis of anatomical
sampling points also provided a weak model; however,
rectal samples were distinctly clustered from the remaining
colonic specimens. These data suggest that the rectal
mucosa harbors a discrete colonic mucosal lipidome that
can be chemically identified (Supp. Figure 1 c).
Using the whole dataset, it was possible to provide
information on the histological subtype of tumors. Only
one patient in this cohort had a GIST, and although they
clustered separately, they were excluded from the analysis.
REIMS was able to distinguish between adenocarcinoma
and mucinous adenocarcinoma with a high degree of
accuracy (Table 2), with an AUC of 0.96 and a sensitivity
and specificity of 94.2 and 83.3 %, respectively. As an
extension, chemical staging models were constructed to
establish how the tumor mucosal lipidome evolves with
advancing stage. The overall accuracy of the staging
model was 74.7 %, with stage 0 cancers (Fig. 4D) and
stage IV cancers clustering separately, and there was
considerable overlap between stages II and III lesions. It
was possible to classify all tumor specimens according to
the lymphatic involvement (Fig. 3) with an accuracy of
83.5 %, although because of the small number of N2
lesions, the sensitivity and specificity was not recordable.
The model for metastatic status had sensitivity for dis-
tinguishing metastatic from non-metastatic disease of
25 % (Supp. Figure 1 f).
During the in vivo resection of polyps or cancers,
numerous sample points are obtained during a single sur-
gical REIMS-augmented procedure, and all of these provide
important biochemical data that are relevant to the summary
histological classification. Therefore, all sampling points
were included (both tumor and NAMs) in the analysis of
prognosis. Histopathology revealed that seven tumors had
lymph node metastases at the time of histopathological
assessment (LN). Seven tumors had extramural vascular
invasion (EMVI), and sixteen tumors had tumor budding
(TB). The overall performance for all patients included in
the analysis was moderate; AUCs of REIMS for all samples
in the cohort for differentiation, tumor budding, LVI, EMVI
and LN involvement were 0.88, 0.87, 0.83, 0.81 and 0.81,
respectively (Fig. 3, Table 2). In general, the specificity of
the technique was greater than the sensitivity, although both
the false-negative and false-positive discovery rate were
variable (Table 2).
Fig. 1 Example spectra from NAM, malignant and adenomatous tis-
sue; the 600–900 m/z range has been selected. Box plots representing
statistically significant phospholipid species from the entire sample
set are demonstrated identifying statistically significant quantitative
changes in lipid expression between tissue types
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To account for the influence on anatomical lipid
expression and the confounding effect of neoadjuvant
therapies, rectal cancers were then examined in isolation.
Four of these patients had undergone neoadjuvant treat-
ment with long-course chemoradiotherapy (LCRT), and
multivariate modeling suggested that this has a persistent
influence on the rectal lipid chemistry, as the model was
able to robustly differentiate those patients treated with
LCRT (Sensitivity 95.7 %, specificity 96.2 %, AUC 0.9).
Two patients had no viable tumor remaining after complete
pathological response to neoadjuvant therapy, however.
Histopathological assessment of these biopsies revealed
fibrosis, and REIMS was able to robustly distinguish this
from healthy tissue with 100 % accuracy (Table 2).
Routine histological reporting outcomes that serve as
established biomarkers of poor prognostic outcome and
which are used to guide future therapy were then used as
arbitrary outcome measures to determine whether REIMS
has the ability to define rectal tumors of poor phenotype.
REIMS was able to differentiate tumors according to tumor
budding (AUC 0.82), differentiation (moderate vs. poor
AUC 0.99), LVI (AUC 0.75), EMVI (AUC 0.98) and nodal
micrometastases (AUC 0.92). The histological correlations
were stronger in the rectal cohort than in the remaining
colonic group suggesting that the lipid analysis has the
capacity to identify chemical signatures associated with a
poor outcome in patients with established rectal cancer.
In vivo development
The in vivo endoscopic REIMS system was set up as
outlined in Fig. 4. A bespoke modified endoscopic
polypectomy snare (Medwork) was developed to allow
optimum transfer of snare diathermy aerosol from the
colonic lumen. Modifications included a series of fenes-
trations in the distal snare sheath and an inbuilt side port in
the snare handle to facilitate connection to the mass
spectrometer (Fig. 4D). A video of the system setup and
live data capture can be seen in the supplementary data.
During the initial experiments, the spectral data were not
Fig. 2 Summary diagnostic colorectal data analyzed by REIMS.
A An LDA scores plot, demonstrating class separation between
normal associated mucosa (NAM), cancer and adenomas. The
confusion matrices showing the sensitivity and specificity of
B NAM versus Tumor C Tumor versus adenoma and D NAM versus
adenoma are demonstrated in the corresponding ROC curves
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provided to the endoscopist or clinical team. The system
was deployed in vivo in five patients undergoing
polypectomy as part of the UK Bowel Cancer Screening
Program, and the demographic data for the patients
recruited to the in vivo work can be seen in supplementary
Table 1. Initial analysis was focused on proof of concept;
therefore, the aim was the optimization of data quality, as
determined by signal-to-noise ratio. Initial experiments
suffered from obstruction of the ion transfer tubing and
thus poor quality signals. However, these were overcome,
and the snare fenestrations were optimized. An example of
the current spectral data quality can be found in the sup-
plementary data (Supp. Figure 3). This demonstrates that
target lipid species as identified by the ex vivo analysis are
visible within the selected m/z charge range, and that they
can be captured in near real time. However, it is not cur-
rently possible to perform a valid multivariate analysis of
its diagnostic strength.
Discussion
Precision surgery for the management of colorectal cancer
requires new technologies that can provide real-time,
objective data on tumor biology for the stratification of
clinical decision-making. The cancer lipidome is rapidly
being realized as a key modulator of cancer biology and
therapeutic response, and it provides a novel window into
tumor biology. It also offers a novel methodology for
in vivo analysis as it can be assessed in near real time.
Some tumors demonstrate a lipogenic phenotype, as
membrane lipids are rapidly synthesized in tumor cells
with a high turnover. Indeed, cancer cells alter lipid
metabolism pathways in order to optimize de novo lipid/
fatty acid output [11]. Our previous work on colorectal
cancer (CRC) metabolism has confirmed markedly altered
lipid patterns in healthy compared to cancerous colorectal
epithelium [12–15]. In addition, recent cell-based work has
Fig. 3 Summary LDA scores plots and associated ROC curves for
associations with established histopathological biomarkers of poor
prognosis. The model was able to identify those patients that had
undergone neoadjuvant LCRT. It was also able to provide robust
models for A tumor budding B differentiation C LVI, D EMVI and
E Lymph node micrometastases
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implicated lipids as critical regulators of cancer not only
structurally (for cell membrane synthesis and stabilization)
but also in cell-signaling and cross talk between cancer
cells and the cancer-adjacent stroma [11].
This is the first study to apply REIMS to a well-phe-
notyped, prospectively recruited colorectal cancer patient
cohort. The aim of this study was to perform a validation
experiment to determine the diagnostic potential of
REIMS in colorectal cancer and to investigate the
potential of REIMS as a point of care, prognostic strati-
fication tool in colorectal cancer. The technology per-
formed with a high degree of accuracy and was able to
robustly distinguish between cancer and NAM, NAM and
adenoma and adenomas and cancers. Although promising,
the number of adenomatous polyps assessed here was
small, and clearly, this requires further analysis in a larger
patient population. It has also not assessed whether
REIMS is able to detect a focus of cancer within a polyp,
which is clearly the gold standard for any technology
making an analysis of suspicious polyps. Sphingolipid
metabolites have been analyzed by high-performance
liquid chromatography (HPLC), and tubular adenomas
have been demonstrated to have increased concentrations
of ceramides compared to control samples. Ceramide, for
example, is characterized by proapoptotic and anti-pro-
liferative properties, and in keeping with the data pre-
sented here, its concentration is known to fall with the
progression to cancer [16]. This suggests that these data
are promising and that REIMS could be used as a tool for
the rapid identification of unknown lesions, or for
involved in vivo margin detection when electrocautery is
deployed during EMR and ESD.
Fig. 4 Summary overview of the iEndoscope platform. This tech-
nology requires minimal deviation from a standard endoscopic set up
with A A typical stack and B Any commercially available endoscope.
C A standard electrosurgical generator is deployed during ‘hot’
endoscopic resection. D We have created a modified snare with a
fenestrated distal sheath for improved efficiency of smoke aspiration.
This was developed in three variants. It has a working channel for
aspiration directly to F a mobile mass spectrometer, with a self
contained spectral database sited in the endoscopy suite. Data are in
practice displayed as a simple visual readout providing data on
predicted histological diagnosis and percentage chances that this is
correct. However, the entire spectra are displayed, and the
600–900 m/z range is shown in more detail, as this range is typically
used in the multivariate analysis. The predominant phospholipid and
triglyceride peaks can be visualized. G An adenoma snared during an
in vivo assessment of the REIMS platform with representative
anatomically discrete lipidomic data captured during hot snare
deployment
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REIMS also demonstrated significant promise in its
ability to identify tumors of a poor prognostic phenotype. It
was able to consistently identify histopathological features
of poor prognosis (tumor budding, differentiation, LVI,
EMVI and LN micrometastases). It is therefore possible
that REIMS could chemically stage cancers in vivo and
that this could be used as an adjunct to standard imaging
technologies to improve preoperative staging and for
stratifying neoadjuvant therapy. Clearly, we have not
demonstrated a mechanistic link between each
histopathological feature and target lipids, but this was not
the aim of the current study. Moreover, we have not
directly compared the performance of REIMS to existing
staging methodologies such as MRI, which requires a
prospective analysis in a larger patient cohort that we are
currently undertaking. What this study demonstrates is that
the chemistry of electrosurgical plumes contains rich and
detailed information on lesions that are likely to confer a
poor prognosis, and these data could therefore be used for
stratifying surgical therapy (e.g., radical resection vs.
endoluminal therapy and organ preservation). Further work
is now needed to identify specific lipid targets and path-
ways that are regulated by each of these processes. Of
specific interest, we were also able to clearly identify rectal
samples previously treated with LCRT (Supp. Figure 2).
This is not in itself a particular surprise, as radiotherapy
will have a significant influence on cell membranes with a
high turnover. However, it does suggest that REIMS is able
to measure the impact of such an intervention in vivo. If it
can be demonstrated that this can be achieved longitudi-
nally, it may serve as a completely novel methodology for
predicting complete pathological response in sensitive
tumors or for identifying early recurrences.
A number of other optical spectroscopic techniques are
being applied to endoscopic characterization of colonic
lesions [17, 18]. An advantage of REIMS over existing
optical spectroscopic strategies, which relay high-resolu-
tion information about lesion structure, is that REIMS
provides information about tumor biology and chemistry.
For some time, it has been known that increasingly aber-
rant lipid metabolism is associated with advancing neo-
plasia [19]. These changes are linked to increasing tumor
invasiveness and metastatic potential. In this study, we
have shown that by analyzing lipid ratios, REIMS corre-
lates with a series of markers indicative of worsening
pathogenicity and thus poorer prognosis in colorectal
cancer. The REIMS method can do this in near real time,
providing the endoscopist or surgeon with immediate
information, which could help to inform decisions about
subsequent treatment. This technology is being deployed
in vivo and delivering reproducible data. More importantly,
it can be deployed as an adjunct to any imaging technol-
ogy, as the endoscope itself does not require any form of
modification. Therefore, REIMS is a tool that can poten-
tially chemically augment other tools deployed in a mini-
mally invasive surgical environment for improving the
accuracy of surgical or endoscopic decision-making.
In this analysis, we have gone beyond the ex vivo work
to demonstrate a translational application of this precision
medicine technology in a first in-man study of colonic
polyps. We have successfully used this approach to record
viable spectra from patients undergoing elective colono-
scopy for polyps. Although this approach has yet to be used
for polyp identification, we are able to obtain high-quality
spectra that contain many of the metabolites identified from
the ex vivo analysis (supp. Figure 3). From this dataset, we
are able to generate spectra with an acceptable signal-to-
noise ratio, with the level of detail necessary for multi-
variate analysis. This proof of concept suggests that
endoscopic REIMS will be suitable for scaling into an
in vivo clinical trial.
The authors acknowledge limitations with this pilot
study. The sample size is small, and validation of our
results in a larger patient cohort is needed. The exact
mechanisms by which REIMS distinguishes clinically rel-
evant variables are also not yet well understood. It is also
possible that there is selection bias here as we were only
collecting ex vivo specimens at surgery. Normal adjacent
mucosa at 10 cm from the primary lesion was available for
examination, as opposed to mucosa directly at the lesion
margin, in order not to compromise the histopathological
integrity of the surgical specimen. Our previous work,
using a complementary mass spectrometry technique,
suggests that there are metabolic differences between
directly adjacent and 10-cm adjacent mucosa [15]. How-
ever, the aim of this feasibility study was to assess the
diagnostic accuracy of REIMS in detecting cancer, for
which 10-cm adjacent mucosa is a suitable control. Energy
is not always deployed in the endoscopic biopsy of polyps,
and it is not always safe to deploy electrocautery. However,
we believe that it is possible to minimize the amount of
energy required to sample polyps so that it may be safely
used, and these can also be assessed ex vivo after endo-
luminal capture. Irrespective of this, these data are
promising and warrant further examination in the context
of a larger-scale study. More importantly, these data will
permit power calculations to be performed for future
prospective work.
In conclusion, by augmenting optical endoscopic and
radiological imaging techniques with information about
tissue biochemistry, REIMS offers a new avenue in per-
sonalized oncological management through the real-time
chemical analysis of the colorectal mucosal lipidome.
Larger-scale studies of this technology are now ongoing to
try to determine whether the data presented here can be
scaled.
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